TY - JOUR
T1 - Palliation of dysphagia in metastatic oesogastric cancers
T2 - An international multidisciplinary position
AU - Levy, Antonin
AU - Wagner, Anna D.
AU - Chargari, Cyrus
AU - Moehler, Markus
AU - Verheij, Marcel
AU - Durand-Labrunie, Jérôme
AU - Kissel, Manon
AU - Chirat, Erick
AU - Burtin, Pascal
AU - Ducreux, Michel
AU - Boige, Valérie
AU - Nilsson, Magnus
AU - Boku, Narikazu
AU - Chau, Ian
AU - Deutsch, Eric
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Malignant dysphagia is the most common symptom in advanced oesogastric cancers patients. Relief of dysphagia allows quality of life improvement, nutritional replenishment and potentially improves prognosis. Chemotherapy alone is effective and should be prioritised in patients with metastatic disease a good performance status, and its impact on dysphagia should be determined before further interventions are planned. Regarding local treatments, the insertion of a covered self-expandable metallic stent is the most commonly used alternative, as it allows for the rapid relief of severe dysphagia. Although several randomised trials have highlighted the role of oesophageal brachytherapy, this technique is often not easily accessible. Contemporary trials are ongoing to better define the role of external radiation therapy. While awaiting these results, external radiation therapy can be considered as a second-best option for patients with a life-expectancy > 3 months. It is important to offer nutritional support and to integrate quality of life measures in the palliative management of dysphagia. This multidisciplinary international position paper aims to propose a decision-making process and highlight randomised trials for the management of malignant dysphagia in metastatic oesogastric cancer patients.
AB - Malignant dysphagia is the most common symptom in advanced oesogastric cancers patients. Relief of dysphagia allows quality of life improvement, nutritional replenishment and potentially improves prognosis. Chemotherapy alone is effective and should be prioritised in patients with metastatic disease a good performance status, and its impact on dysphagia should be determined before further interventions are planned. Regarding local treatments, the insertion of a covered self-expandable metallic stent is the most commonly used alternative, as it allows for the rapid relief of severe dysphagia. Although several randomised trials have highlighted the role of oesophageal brachytherapy, this technique is often not easily accessible. Contemporary trials are ongoing to better define the role of external radiation therapy. While awaiting these results, external radiation therapy can be considered as a second-best option for patients with a life-expectancy > 3 months. It is important to offer nutritional support and to integrate quality of life measures in the palliative management of dysphagia. This multidisciplinary international position paper aims to propose a decision-making process and highlight randomised trials for the management of malignant dysphagia in metastatic oesogastric cancer patients.
KW - Consensus
KW - Quality of life
KW - Supportive care
KW - Upper gastrointestinal cancer
UR - http://www.scopus.com/inward/record.url?scp=85086606786&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2020.04.032
DO - 10.1016/j.ejca.2020.04.032
M3 - Review article
C2 - 32563014
AN - SCOPUS:85086606786
SN - 0959-8049
VL - 135
SP - 103
EP - 112
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -